Cellular and T cell engager Immunotherapy
SWASTH: Phase 1/2 Study of Ribrecabtagene Autoleucel, a BCMA–Directed CAR-T Cell Therapy, in Relapsed-Refractory Multiple Myeloma
Akhil Kumar, MD (he/him/his)
CHIEF MEDICAL OFFICER
AURIGENE ONCOLOGY LIMITED
BANGALORE, Karnataka, India